RxDoctor Payments Data

Alithia Maeurer

Physician Assistant · Tannersville, NYNPI 1487786489

Payments from drug & device makers

$964in general payments, 2019–2025

Across 48 payments — averaging $20.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$422
  • Novo Nordisk$229
  • Pfizer$136
  • Lilly USA, LLC$57
  • Exact Sciences$26
  • Abbott$20
  • plus $73 from 4 others

What the payments were for

  • Food & beverage$964100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$964 in reported general payments places this provider in the 75th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$67,006
Medicare patients
222
Services billed
1,044

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide102$97,371
EliquisApixaban51$43,417
TrulicityDulaglutide32$41,815
RybelsusSemaglutide33$38,620
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$35,163
FarxigaDapagliflozin Propanediol38$31,891
OxycontinOxycodone Hcl19$28,772
JardianceEmpagliflozin24$19,921
LinzessLinaclotide14$14,517
TradjentaLinagliptin18$11,807
JanuviaSitagliptin Phosphate11$7,528
SymbicortBudesonide/Formoterol Fumarate18$7,383
Albuterol Sulfate HfaAlbuterol Sulfate156$5,418
Lantus SolostarInsulin Glargine,hum.Rec.Anlog36$4,503
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate19$3,515

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$229$138,724149 claims
PfizerEliquis$136$43,41751 claims
Lilly USA, LLCTrulicity$57$41,81532 claims
AstraZenecaFarxiga, Symbicort$422$39,27456 claims
GSKTrelegy Ellipta$20$35,16344 claims
Boehringer IngelheimJardiance, Tradjenta$20$31,72842 claims
AbbVieLinzess, Synthroid$17$16,30347 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Tannersville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →